David Quigley

David Quigley is a faculty researcher at the University of California San Francisco (UCSF), where he leads research on prostate cancer genomics and therapy resistance. His work focuses on understanding how genomic and epigenomic alterations in tumors influence patient outcomes and treatment response in advanced prostate cancer.

Education:

• BA in Computer Science, Carleton College, 1998
• MA in Biomedical Informatics, Columbia University, 2006
• PhD in Genetics, University of Oslo, 2014

Dr. Quigley's research lies at the intersection of cancer biology, genomics, and computational methods. He uses large-scale genome sequencing and machine learning to identify non-coding structural variants, epigenetic changes, and transcriptional drivers associated with resistance to targeted therapies in metastatic prostate cancer. His recent work includes mapping accessible chromatin, studying AR signaling resistance, and developing predictive models for clinical outcomes.

His recent publications (2024–2025) span high-impact journals such as Nature Genetics, Nature Cell Biology, Cancer Discovery, and Journal of Clinical Oncology, reflecting a strong focus on epigenomics, therapy resistance, spatial profiling, and health disparities in prostate cancer. Collaborative in nature, his research involves multi-institutional teams and integrates experimental and computational approaches.

Scientific Awards:

• National Merit Scholar
• B.A. Magna Cum Laude
• M.A. with honors
• AACR Scholar in Training Award
• Prostate Cancer Foundation Young Investigator Award (2018)
• BRCA Foundation Young Investigator Award (2024)
• Robert Sutherland Award, PacRim Breast and Prostate Cancer Meeting (2024)
• Outstanding Faculty Mentorship Award, UCSF Students of the Graduate Division

Dr. Quigley is the Principal Investigator on a DOD-funded project (2024–2027) aimed at discovering transcriptional drivers in therapy-resistant prostate cancer and a co-PI on a Prostate Cancer Foundation grant using machine learning to advance drug development. He is actively involved in mentoring and collaborative science, contributing to major research consortia such as the SU2C/PCF West Coast Prostate Cancer Dream Team. His lab integrates clinical data, tumor genomics, and advanced computational models to improve risk stratification and therapeutic strategies for prostate cancer patients.

Labs and Research Teams: His research is conducted in close collaboration with the laboratory of Dr. Felix Feng at UCSF, a leading group in prostate cancer genomics. He is part of the SU2C/PCF West Coast Dream Team and contributes to the Benioff Initiative for Prostate Cancer Research.